Healthcare Realty Trust Q2: Normalized FFO of $0.41, $42.8M in Impairments, and a $75M Buyback
HR sits 39% above its 52-week low of $15.285.
Summary
Healthcare Realty Trust reported Q2 normalized FFO of $0.41 per share, flat year-over-year, alongside $42.8 million in impairments and a $75 million buyback. The balance sheet was strengthened with a new $400 million term loan and a $700 million exchangeable notes issuance.
Key Events · Earnings and Guidance · HR
-
Q2 Normalized FFO Flat at $0.41
Normalized FFO per share held steady at $0.41 compared to Q2 2025, as reduced interest expense and G&A costs offset lower rental income from dispositions.
-
$42.8M in Real Estate Impairments
Reflecting ongoing portfolio pruning, the company recorded $42.8 million in impairments on properties sold or with changed holding periods, down from $151 million a year ago.
-
$75M Share Repurchase Executed
As part of a strategy to offset dilution from the exchangeable notes, 3.8 million shares were repurchased during Q2 at an average price of $19.58, totaling $75 million.
-
Liquidity Bolstered with New Facilities
Ample liquidity was secured through a $400 million delayed-draw term loan and $276 million in outstanding commercial paper, complementing $1.2 billion available on the revolver.
Analysis · HR · Real Estate & Construction
Healthcare Realty Trust delivered Q2 normalized FFO of $0.41 per share, flat year-over-year, while its net loss narrowed sharply to $43.6 million from $157.9 million a year ago. The quarter included $42.8 million in real estate impairments and a $75 million share repurchase tied to the recent exchangeable notes offering. Bolstering liquidity, the company also secured a new $400 million delayed-draw term loan and had $276 million in commercial paper outstanding. The results highlight ongoing portfolio repositioning through asset sales and impairments, offset by lower interest expense and G&A savings.
At the time of this filing, HR was trading at $21.18 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $15.29 to $22.04. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.